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ABSTRACT 
Background. Myocardial fibrosis is characterized by excessive cross-linking (CCL) and 
deposition of collagen type I (CD) and is involved in the left ventricular stiffening and left 
ventricular diastolic dysfunction (LVDD). We investigated whether the effect of 
spironolactone on LVDD in patients with heart failure with preserved ejection fraction 
(HFpEF) depends on its effects on CCL and/or CD.  
Methods and Results. We investigated n=381 HFpEF patients from the multicenter, 
randomized and controlled Aldo-DHF trial with measures of the E:e’ ratio. The ratio of 
serum carboxy-terminal telopeptide of collagen type I to serum matrix metalloproteinase-1 
(CITP:MMP-1, an inverse index of myocardial CCL), and serum carboxy-terminal 
propeptide of procollagen type I (PICP, a direct index of myocardial CD), were determined 
at baseline and after 1-year treatment with spironolactone 25mg once-daily or placebo. 
Patients were classified by CITP:MMP-1 and PICP tertiles at baseline. Whereas 
CITP:MMP-1 tertiles at baseline interacted (P<0.05) with spironolactone effect on E:e’, 
PICP tertiles did not. In fact, whereas spironolactone treatment did not modify E:e’ in 
patients with lower CITP:MMP-1 levels, this ratio was significantly reduced in the 
remaining spironolactone-treated patients. Of interest, PICP was unchanged in patients with 
lower CITP:MMP-1 levels but was reduced in the remaining spironolactone-treated 
patients. 
Conclusions. A biochemical phenotype of high CCL identifies HFpEF patients resistant to 
the beneficial effects of spironolactone on LVDD. It is suggested that excessive CCL, 
which stabilizes collagen type I fibres, diminishes the ability of spironolactone to reduce 
collagen type I deposition in these patients. 
 
Key words: Heart failure with preserved ejection fraction, spironolactone, left ventricular 
diastolic function, biomarkers of myocardial fibrosis, carboxy-terminal propeptide of 
procollagen type I, carboxy-terminal telopeptide of collagen type I, metalloproteinase-1.   
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Heart failure (HF) with preserved ejection fraction (HFpEF) is currently considered an 
epidemic, accounting for up to 50% of all HF cases, showing a consistent trend of 
increasing prevalence over the next years, with significant morbidity and mortality rates.1,2 
Compared to HF with reduced ejection fraction, progress in the treatment of HF has been 
much less pronounced in patients with HFpEF, in which personalization of 
pharmacotherapy regimens remains poorly defined.3-5 
 Myocardial fibrosis contributes to ventricular stiffness and impaired relaxation in 
patients with HFpEF.6-8 Specifically, excessive myocardial collagen cross-linking, a 
process catalyzed by the enzyme lysyl oxidase (LOX) which increases the insolubility, 
stiffness and resistance to degradation of the collagen fibre (mainly type-I),9 and increased 
deposition of collagen type I, are related to elevated filling pressures in patients with 
HFpEF.10 Therefore, the functional impact of myocardial fibrosis in HFpEF patients is not 
just a matter of the quantity (i.e., severity of deposition) but also of the quality (i.e. degree 
of cross-linking among collagen fibrils) of the collagen type I fibres.  
The carboxy-terminal propeptide of procollagen type I (PICP) is generated during 
the extracellular conversion of procollagen type I into collagen type I by the enzyme 
procollagen carboxy-terminal proteinase.11 A net release from the heart into the circulation 
has been reported in HF,12 suggesting a cardiac origin for systemic PICP in this syndrome. 
Serum PICP levels correlate with myocardial collagen and collagen type I deposition.12,13 
On the other hand, as collagen cross-linking determines the resistance of the collagen fibre 
to metalloproteinase (MMP) degradation, the higher the cross-linking of collagen type I 
fibres, the lower the cleavage of the carboxy-terminal telopeptide of collagen type I (CITP) 
by the enzyme MMP-1. Thus, serum CITP:MMP-1 ratio has been shown to be inversely 
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correlated with myocardial collagen cross-linking.14 Interestingly, the CITP:MMP-1 ratio is 
independently associated with the risk of HF hospitalization in HF patients.14  
The Aldo-DHF study, a multicenter, prospective, randomized, double-blind, 
placebo-controlled trial performed in n=422 ambulatory patients with HFpEF showed that 
1-year treatment with spironolactone was associated with a reduction in left ventricular 
(LV) filling pressures, LV mass and circulating amino-terminal pro-brain natriuretic 
peptide (NT-proBNP) levels without changes in maximal exercise capacity.15 It has been 
suggested that spironolactone-induced improvement of left ventricular diastolic dysfunction 
(LVDD) may be related to its anti-fibrotic actions.16-18 However, it is unknown whether 
spironolactone is able to affect the degree of myocardial collagen type I content, stiffness 
and resistance to degradation in patients with HFpEF. In addition, it is not known whether 
these characteristics of the collagen fibre may impact on the spironolactone’s capacity to 
improve LVDD in HFpEF patients. Therefore, the aim of the current analysis was 2-fold: i) 
assess the impact of spironolactone treatment on biomarkers of myocardial fibrosis, not 
only in terms of collagen deposition (as assessed by serum PICP) but also in terms of 
collagen cross-linking (as assessed by serum levels of the CITP:MMP-1 ratio), and ii) 
investigate whether the characteristics of myocardial fibrosis at baseline interact with 
spironolactone effects on LVDD. 
METHODS 
Aldo-DHF was a prospective, randomized, placebo-controlled, double-blind multicentre 
study. The trial design and primary results of Aldo-DHF have been previously published.15 
Briefly, eligible patients were enrolled and randomized (1:1 ratio) to spironolactone 25mg 
once daily or matching placebo and followed over 12 months. Patients with stable HFpEF 
defined as NYHA class II or III heart failure symptoms, LVEF≥50% at rest, 
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echocardiographic evidence of grade ≥ I diastolic dysfunction or atrial fibrillation (AF), and 
peak VO2≤25 mL/kg/min were eligible for participation. Major exclusion criteria included: 
prior documented LVEF≤40%, significant coronary artery disease, myocardial infarction or 
coronary artery bypass graft surgery within 3 months, definitive or probable pulmonary 
disease [vital capacity <80% or forced expiratory volume in 1s (FEV1)<80% or reference 
values on spirometry], body mass index ≥36 kg/m2, or serum creatinine > 1.8mg/dL. The 
study protocol was reviewed and approved by the institutional review board of each 
participating center, and all patients provided written informed consent prior to enrolment. 
Aldo-DHF was conducted in accordance with national laws, guidelines for good clinical 
practice, and the Declaration of Helsinki. 
Circulating biomarkers 
Biomarker assessments were performed in the serum collected at baseline and at study end 
12 months after randomization. Analysis of CITP was performed using an enzyme-linked 
immunosorbent assay (ELISA) developed by USCN Life Science. The inter-assay and 
intra-assay coefficients of variation were 10.5% and 11.6%, respectively. The lower limit of 
detection was 44.3 pg/ml. Total serum MMP-1 was measured by an ELISA method (GE 
Healthcare). The inter-assay and intra-assay coefficients of variation were 12.4% and 7.0%, 
respectively. The lower limit of detection was 1.7 ng/ml. CITP and MMP-1 were expressed 
in molarity and the CITP:MMP-1 ratio was calculated in each patient as previously 
reported.14 Serum PICP was measured by using the EIA MicroVue CICP (Quidel 
Corporation). The inter-assay and intra-assay coefficients of variation were 12.0% and 
8.1%, respectively. The lower limit of detection was 0.2 ng/ml.  
Statistical analysis 
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The study population was categorized into tertiles of the serum CITP:MMP-1 ratio and 
PICP levels at baseline. Linear test for trend were used to assess any tendency across the 
different subgroups. The distributions of all analyzed biomarkers were normalized by a 
logarithmic transformation. 
 Associations between variables at baseline or between changes in variables over 12 
months after treatment were assessed using a bivariate correlation (model 1), and were 
correlated as partial correlation coefficients corrected for sex and age only (model 2), and 
as partial correlation coefficients corrected for sex, age, AF, mean arterial pressure (MAP), 
estimated glomerular filtration rate (eGFR), hemoglobin, and NT-proBNP (model 3).19 The 
Benjamini and Hochberg multiple-test correction (false discovery rate of 10%) was applied. 
 Testing for interaction between the effect of treatment (spironolactone or placebo) 
on LVDD and non-invasively assessed myocardial fibrosis was conducted in patients 
categorized into tertiles according to serum CITP:MMP-1 ratio or PICP levels by analysis 
of covariance with the follow-up value of the E:e’ ratio as the dependent variable, the 
baseline E:e’ ratio as covariate, and treatment, subgroup variable, and their respective 
interaction terms as factor variables. Analyses over 12 months of follow-up to evaluate the 
effects of spironolactone therapy vs placebo were performed by analysis of covariance, 
binary, or ordinal logistic regression with the follow-up value as the dependent variable, 
treatment as a factor, and the baseline value as the continuous or categorical covariate, as 
appropriate for quantitative, binary, or ordinal categorical variables, on each subgroup of 
patients. Between groups comparisons are presented as mean differences or odds ratios. 
Biomarkers were analyzed on the logarithmic scale, and the results were transformed back 
by the exponential function, leading to a geometric mean instead of a mean difference. P-
values for the interaction term of treatment with E:e’ and PICP were calculated in each 
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subgroup of patients according to tertiles of the serum levels of CITP:MMP-1 ratio using a 
univariate analysis of variance (ANOVA) model with repeated measurements.  
 Values are expressed as mean±SD and median (interquartile range [IQR]) for 
continuous variables, and as numbers and percentages for categorical variables. A P value 
≤0.05 was considered statistically significant, and all statistical tests were two-sided. The 
statistical analyses were performed by using SPSS (15.0 version) and STATA (12.1 
version). 
RESULTS 
A total of n=422 patients were enrolled in the Aldo-DHF trial from March 2007 to April 
2011. Of these, n=415 had available blood samples and n=381 had values of CITP, MMP-1 
and PICP at baseline (Fig. S1, baseline sample set [BSS]). In addition, values of PICP and 
of CITP and MMP-1 were available at 12 months in n=370 patients (Fig. S1, follow-up 
sample set [FSS]). 
Analyses at baseline 
In the BSS, the distribution of serum CITP:MMP-1, as a marker of collagen cross-linking, 
departed from normality and was positively skewed (P<0.0001). The median of serum 
CITP:MMP-1 was 3.91 (IQR: 1.86-6.68). Patients were categorized at baseline according 
to tertiles of increasing serum CITP:MMP-1 ratio levels. Diastolic and mean blood pressure 
increased across CITP:MMP-1 tertiles probably due to a decreasing percentage of patients 
treated with angiotensin converting enzyme inhibitors or angiotensin II type-1 receptor 
blockers along the tertiles (Table 1). Of interest, patients showed better diastolic function 
(i.e. lower E:e’ ratio) and improved parameters of exercise capacity (i.e. lower VE/VCO2 
slope and higher maximum exercise duration and Borg score) with increasing CITP:MMP-
1 values (Table 2). Although weak, a continuous inverse association was found between 
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CITP:MMP-1 ratio and the E:e’ ratio, not reaching statistical significance after adjustment 
for confounders (Table S1). In addition, a direct continuous significant correlation was 
found between CITP:MMP-1 ratio and the Borg score, independently of confounders 
(Table S1). 
In all patients, the distribution of serum PICP, as a marker of collagen deposition, 
departed from normality and was positively skewed (P<0.0001). The median of serum 
PICP was 111 ng/ml (IQR: 92.0-136). Patients were categorized at baseline according to 
tertiles of increasing PICP serum levels (Tables S2 and S3). Sodium levels were greater 
with higher PICP values (Table S2). Left atrial (LA) volume index, E-wave velocity and 
NT-proBNP increased across tertiles of PICP (Table S3). Continuous direct associations 
were found between PICP and LA volume index and NT-proBNP, independently of 
confounders in models 2 and 3 (Table S1).  
Analyses after twelve months of treatment  
Whole cohort 
Over the course of 12 months, treatment with spironolactone showed similar effects in the 
subgroup of patients included in the FSS, as in those reported in the original Aldo-DHF 
study15 (Table S4). Levels of serum PICP decreased (P=0.050) after 12 months of treatment 
with spironolactone compared with placebo (Table S4, Fig S2A). The serum CITP:MMP-1 
ratio remained unchanged after 12 months of treatment (Table S4, Fig S2B). A weak 
correlation was found between changes in the E:e’ ratio and changes in serum PICP in all 
patients in the FSS set (r=0.111, P=0.033) (Fig S2C) that remained statistically significant 
after adjustment for confounders in model 2 (P=0.028) but did not reach statistical 
significance after full adjustment in model 3 (P=0.065). In addition, changes in serum PICP 
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were directly correlated with changes in serum NT-proBNP (r=0.146, P=0.005) (Fig S2D) 
independently of confounders in models 2 and 3 (P≤0.022).  
Analyses by tertiles 
Tests for interaction to globally assess the heterogeneity of treatment effects on the E:e’ 
ratio among tertiles of the baseline variables CITP:MMP-1 and PICP have been performed. 
A significant interaction was detected between CITP:MMP-1 tertiles and the effect of 
spironolactone on E:e’ (P=0.014). Further analyses adjusting by age and prevalence of 
coronary artery disease at baseline confirmed this interaction. No significant interaction 
was detected when the categorization was based on PICP tertiles. 
Once the heterogeneity of treatment was confirmed for the CITP:MMP-1-based 
categorization, we analyzed treatment effects within each one of the CITP:MMP-1 tertiles. 
At baseline, no differences were found in any of the demographic, clinical and biochemical 
parameters between patients treated with spironolactone or placebo, in any of the 
CITP:MMP-1 tertile-based subgroups (Table S5 and S6). After 12 months of treatment, 
spironolactone did not modify the E:e’ ratio in patients with low CITP:MMP-1 ratio levels 
(1st tertile, Fig. 1A) (Table 3), but was associated with a significant decrease in the E:e’ 
ratio in patients with medium or high CITP:MMP-1 ratio values (2nd and 3rd tertiles, Fig 1B 
and 1C, respectively) as compared with placebo. In patients with low levels of the 
CITP:MMP-1 ratio, the circulating levels of PICP were unchanged with spironolactone 
(Fig 2A), whereas in patients with medium or high CITP:MMP-1 ratio values, the decline 
in E:e’ was accompanied by a reduction in the circulating levels of PICP as compared with 
baseline (2nd and 3rd tertiles, Fig 2B and 2C, respectively). Of interest, only spironolactone-
treated patients with the highest CITP:MMP-1 ratio values showed reduction in NT-
proBNP circulating levels with treatment, whereas placebo-treated patients did show 
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similar peptide levels at the end of treatment as compared with baseline (Fig S3). No effects 
of treatment on NT-proBNP circulating levels were observed in the remaining patients (Fig 
S3). 
 In Aldo-DHF, a slight reduction in 6 minute walk distance after 1 year 
spironolactone versus placebo was observed.15 Interestingly, this decline in exercise 
capacity was detectable in those patients with a low CITP:MMP-1 ratio (Table 3).  
DISCUSSION 
The main findings of this study are the following: 1) in HFpEF patients, spironolactone 
therapy reduces serum levels of the biomarker of collagen deposition, PICP, but does not 
modify the serum levels of the biomarker of collagen cross-linking, the CITP:MMP-1 ratio; 
2) spironolactone did not improve diastolic function in the subset of patients with lower 
CITP:MMP-1 ratio (i.e., a higher degree of collagen cross-linking) and 3) spironolactone 
does not reduce serum levels of PICP in the subset of patients with lower CITP:MMP-1 
ratio. To our knowledge, this is the first study analyzing the effects of spironolactone on the 
quantity and the quality of the myocardial collagen network, as assessed non-invasively by 
using circulating biomarkers that exhibit histologically proven associations with these 
characteristics of the collagen tissue, in patients with HFpEF. In addition, to the best of our 
knowledge, this is the first time that the impact of the characteristics of myocardial fibrosis 
on the effects of spironolactone on LV diastolic function has been evaluated. 
 We have observed that, at baseline, HFpEF patients with low serum levels of the 
CITP:MMP-1 ratio exhibit higher E:e’ ratio. These findings support previous clinical 
evidences of an association between myocardial collagen cross-linking and increased LV 
filling pressures in patients with HF20 and specifically in patients with HFpEF.10 In 
addition, we describe for the first time that low levels of the CITP:MMP-1 ratio associate 
12 
 
with parameters reflecting worse cardiopulmonary exercise performance. On the other 
hand, we found that PICP directly associates with NT-proBNP and LA volume index, in 
HFpEF patients at baseline. In this regard, associations of PICP with NT-proBNP and LA 
size have been previously reported in HF patients with reduced EF.21,22 Overall, the 
observations at baseline suggest that myocardial fibrosis, considering its qualitative and 
quantitative aspects, is related to LVDD and lower exercise performance in patients with 
HFpEF. 
Previous clinical studies demonstrate that spironolactone reduces the circulating 
serum levels of PICP in asymptomatic patients with LVDD.23 This study reports for the 
first time that spironolactone treatment is associated with a reduction in serum PICP in 
patients with HFpEF. In addition, we have observed that treatment with spironolactone is 
not able to modify the serum levels of CITP:MMP-1 in these patients. Therefore, 
spironolactone seems capable of affecting the myocardial collagen content but unable to 
modify the characteristics of the collagen fibre that determine its insolubility, stiffness and 
resistance to degradation. Experimental studies demonstrate that aldosterone increases the 
expression of LOX24-26 (the myocardial enzyme responsible for collagen cross-linking), and 
the tissue inhibitor of metalloproteinases-1 (TIMP-1),27 indicating that this hormone may 
also contribute to myocardial fibrosis by incrementing the stability of the collagen fibre. In 
this regard, it is plausible that incomplete mineralocorticoid receptor blockade with 
spironolactone in the myocardium might still allow for aldosterone- or another pro-fibrotic 
molecules-induced collagen cross-linking and deposition. It is uncertain whether agents 
with greater mineralocorticoid receptor blockage at the myocardial level may be able to 
inhibit aldosterone actions with sufficient efficacy to influence on the quantitative and 
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qualitative characteristics of the myocardial collagen network. These possibilities are 
speculative and further studies are necessary to fully clarify these aspects. 
Interestingly, we have observed that spironolactone did not improve LV diastolic 
function and failed to reduce collagen deposition (as assessed by serum PICP) in patients 
exhibiting lower CITP:MMP-1 serum levels, or in other words, higher collagen cross-
linking, at baseline (see Figure 3). Given that the degree of cross-linking is associated with 
high filling pressures in HFpEF patients,10 it is tempting to speculate that the incapacity of 
spironolactone to improve LV diastolic function in patients with high cross-linking may be 
related to its inability to affect the stability of the collagen fibre. Therefore, these results 
suggest that spironolactone could be a more successful treatment in HFpEF patients with a 
phenotype indicative of a non-excessive degree of collagen cross-linking, in which a higher 
efficacy to modulate collagen metabolism and improve LV function may be achieved.  
In the Aldo-DHF original study,15 spironolactone was associated with a subtle 
reduction in submaximal exercise capacity. Interestingly, the current subanalysis reveals 
that only in patients with high collagen cross-linking, exhibiting symptoms of altered 
cardiopulmonary exercise performance at baseline, spironolactone treatment is associated 
with a reduction of the 6-minute walk distance. In this regard, we may speculate that those 
patients with high collagen cross-linking exhibiting resistance to spironolactone-induced 
improvement on LV diastolic function may be more susceptible to the treatment side-
effects of the drug on submaximal exercise capacity.  
Of interest, some evidence suggests that other therapeutic options are able to target 
the excess of collagen cross-linking in the myocardium. For instance, the loop diuretic 
torasemide is associated with significant reductions in both the severity of the deposition of 
collagen type I fibres and the degree of myocardial cross-linking, as well as with significant 
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improvement of LV function and NYHA functional class in patients with HF.13,28 None of 
these effects were observed in furosemide-treated HF patients.13,28 In addition, the losartan 
metabolite EXP3179 prevents excessive myocardial collagen cross-linking, among other 
anti-fibrotic actions, in a model of experimental hypertension.29 Collectively, these findings 
allow us to suggest further clinical designs to investigate whether these compounds may be 
optional drugs to complement therapeutic strategies for the personalized treatment of 
HFpEF patients with a biochemical phenotype indicative of excessive collagen cross-
linking.  
Some limitations need to be acknowledged. First, this is a post-hoc analysis re-
evaluating the Aldo-DHF clinical trial by subgroups. Clinical trial subanalyses are prone to 
false negative results since they may be inadequately powered to uncover treatment effect 
differences, even in the presence of true treatment effect modification. Nonetheless, these 
analyses revealed significant treatment effect differences in subgroups exhibiting similar 
sample size. Second, the reduction in sample size due to CITP:MMP-1 tertile categorization 
may have affected the statistical power to detect significant differences in between-subject 
analyses comparing spironolactone vs placebo effects on the biomarkers PICP and NT-
proBNP. Nonetheless, the less conservative within-subject comparisons did detect 
significant effects of spironolactone on these biomarkers. Third, covariates unaccounted for 
in the analyses and potential problems related with multiplicity could have influenced the 
findings obtained. Fourth, these findings have not been validated in an independent cohort. 
Therefore, we believe that the results showing the impact of collagen cross-linking on the 
spironolactone effects on LV dysfunction and collagen deposition should be hypothesis-
generating and need to be confirmed in larger prospectively designed studies.  
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In conclusion, this study shows for the first time that spironolactone is unable to 
modify the circulating levels of a biomarker of myocardial collagen cross-linking, the 
CITP:MMP-1 ratio, in HFpEF patients. In addition, we describe for the first time that 
patients with low serum levels of this biomarker before treatment, indicative of a high 
degree of myocardial collagen cross-linking, do not respond to spironolactone in terms of 
LV diastolic function improvement and reduction of the myocardial collagen content (see 
figure 3). On the whole, these data suggest that the ability of spironolactone to reduce 
myocardial fibrosis and improve LV diastolic function is determined by the stability of the 
collagen fibre in HFpEF patients. These findings support the notion that a precise 
biomarker-based phenotyping of patients with HFpEF is critical to advance in the field of 
HFpEF therapy. 
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LEGENDS  
Figure 1. Peak early transmitral ventricular filling velocity to early diastolic tissue Doppler 
velocity (E:e’) according to study treatment in patients with low (A), medium (B) and high 
(C) serum carboxy-terminal telopeptide of collagen type I to matrix metalloproteinase-1 
ratio levels as classified by tertiles. Data are expressed as mean values and 95% confidence 
interval at baseline and at 12 months in patients treated with placebo (○) or with 
spironolactone (). *P<0.05 spironolactone at 12 month vs baseline, **P<0.01 
spironolactone at 12 month vs baseline. 
Figure 2. Serum carboxy-terminal propeptide of procollagen type I (PICP) levels (log) 
according to study treatment in patients with low (A), medium (B) and high (C) serum 
carboxy-terminal telopeptide of collagen type I to matrix metalloproteinase-1 ratio levels as 
classified by tertiles. Data are expressed as mean values and 95% confidence interval at 
baseline and at 12 months in patients treated with placebo (○) or with spironolactone (). 
Medians (interquartile range) for values at baseline and at 12 months are shown below each 
graph *P<0.01 spironolactone at 12 month vs baseline. 
Figure 3. Diagrammatic representation of the spironolactone effects in patients with low or 
high levels of myocardial collagen cross-linking, as assessed by high or low circulating 
values of the carboxy-terminal telopeptide of collagen type I to the metalloproteinase-1 
(CITP:MMP-1) ratio, respectively. In the process of degradation of the collagen type I fibre 
within the myocardial interstitum, MMP-1 cleaves a small C-terminal telopeptide or CITP. 
A higher degree of cross-linking between collagen type I fibrils increases their resistance to 
degradation by MMP-1, generating a lower amount of CITP. Both MMP-1 and CITP reach 
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the systemic circulating and thus can be measured by specific enzyme-linked 
immunosorbent assay methods. Only in patients with a high CITP:MMP-1 ratio, indicative 
of a low collagen-cross-linking and therefore a lower resistance of the collagen type I fibre 
to degradation, treatment with spironolactone is able to reduce myocardial collagen content 
(as assessed by the biomarker of myocardial collagen content carboxy-terminal propeptide 
of procollagen type I or PICP), and improve diastolic function (as assessed by the E/e’ 
ratio). 
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Table 1. Demographic, clinical and biochemical characteristics at baseline in all patients and 
in patients classified according to CITP:MMP1 ratio tertiles 
 
Total 
(n=381) 
 CITP:MMP-1 ratio tertiles 
P for 
trend  
 1st  
(n=127) 
2nd  
(n=127) 
3rd  
(n=127) 
CITP:MMP-1 ratio   <2.50 2.50-5.49 >5.49  
Demographics       
Age, years 67.1 ± 7.6  68.0 ± 7.5 67.1 ± 7.8 66.1 ± 7.6 0.052 
Male gender, n (%) 182 (47.8)  61 (48.0) 61 (48.0) 60 (47.2) 0.90 
Medical History, n (%)       
Hospitalized within 12 months 143 (37.5)  48 (37.8) 48 (37.8) 47 (37.0) 0.90 
Coronary artery disease 152 (39.9)  59 (46.5) 50 (39.4) 43 (33.9) 0.041 
History of myocardial infarction 63 (16.5)  29 (22.8) 16 (12.6) 18 (14.2) 0.06 
Atrial fibrillation 63 (16.5)  25 (19.7) 20 (15.7) 18 (14.2) 0.24 
Hypertension 349 (91.6)  118 (92.9) 119 (93.7) 112 (88.2) 0.18 
Hyperlipidaemia 225 (59.1)  72 (56.7) 77 (60.6) 76 (59.8) 0.61 
Diabetes mellitus 62 (16.3)  22 (17.3) 20 (15.7) 20 (15.7) 0.73 
Cerebrovascular diseases 40 (10.5)  16 (12.6) 14 (11.0) 10 (7.9) 0.22 
Peripheral arterial occlusive disease 15 (3.9)  2 (1.6) 9 (7.1) 4 (3.1) 0.52 
COPD 13 (3.4)  4 (3.1) 5 (3.9) 4 (3.1) 0.99 
Physical examination       
BMI, kg/m2 29.0 ± 3.5  28.6 ± 3.7 29.5 ± 3.4 28.9 ± 3.5 0.43 
SBP, mmHg 136 ± 18.3  133 ± 19.0 140 ± 18.1 136 ± 17.5 0.19 
DBP, mmHg 79.3 ± 11.0  76.3 ± 10.4 80.4 ± 11.5 81.2 ± 10.4 0.0004 
MAP, mmHg 98.2 ± 11.8  95.2 ± 11.5 99.6 ± 11.9 99.6 ± 11.6 0.003 
HR, beats/min 66.7 ± 11.6  65.7 ± 10.1 67.0 ± 12.5 67.5 ± 11.9 0.23 
Signs and symptoms, n (%)       
NYHA class       
    II 326 (85.6)  111 (87.4) 104 (81.9) 111 (87.4) 
0.99 
    III 55 (14.4)  16 (12.6) 23 (18.1) 16 (12.6) 
Peripheral edema 154 (40.4)  52 (40.9) 52 (40.9) 50 (39.4) 0.80 
Paroxysmal nocturnal dyspnoea 66 (17.3)  17 (13.4) 23 (18.1) 26 (20.5) 0.14 
Nocturnal cough 60 (15.7)  22 (17.3) 19 (15.0) 19 (15.0) 0.50 
Laboratory measures       
Hemoglobin, g/dL 13.8 ± 1.2  13.6 ± 1.2 13.8 ± 1.1 13.9 ± 1.2 0.08 
Sodium, mmol/L 140 ± 3.0  140 ± 3.2 141 ± 2.7 140 ± 3.0 0.75 
Potassium, mmol/L 4.2 ± 0.4  4.2 ± 0.4 4.2 ± 0.4 4.2 ± 0.4 0.49 
eGFR, mL/min/1.73 m2 75.7 ± 19.2  73.2 ± 20.3 76.2 ± 17.4 77.7 ± 19.5 0.06 
Baseline medications, n (%)       
ACE inhibitor or ARB 292 (76.6)  107 (84.3) 97 (76.4) 88 (69.3) 0.005 
Beta-blocker 275 (72.2)  95 (74.8) 91 (71.7) 89 (70.1) 0.40 
Diuretics 202 (53.0)  71 (55.9) 70 (55.1) 61 (48.0) 0.21 
Calcium channel blocker 95 (24.9)  26 (20.5) 37 (29.1) 32 (25.2) 0.39 
Lipid-lowering drug 208 (54.6)  71 (55.9) 69 (54.3) 68 (53.5) 0.71 
Spironolactone 195 (51.2)  68 (53.5) 61 (48.0) 66 (52.0) 0.80 
CITP means carboxy-terminal telopeptide of collagen type I; MMP-1, matrix metalloproteinase-1; COPD, chronic 
obstructive pulmonary disease; BMI, body mass index; SBP, systolic blood pressure; DBP, diastolic blood pressure; 
MAP, mean arterial pressure; HR, heart rate; NYHA, New York Heart Association; eGFR, estimated glomerular 
filtration rate; ACE, angiotensin converting enzyme; ARB, angiotensin II type 1 receptor blockers . Values are 
expressed as mean ± SD and categorical variables as numbers and percentages. 
. 
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Table 2. Echocardiography, biomarkers, exercise testing and quality of life at baseline in all 
patients and in patients categorized according to CITP:MMP1 ratio tertiles 
 
Total 
(n=381) 
 CITP:MMP-1 ratio tertiles 
P for 
trend  
 1st  
(n=127) 
2nd  
(n=127) 
3rd  
(n=127) 
CITP:MMP-1 ratio   <2.50 2.50-5.49 >5.49   
Echocardiography        
LVEF, % 67.7 ± 7.9  67.9 ± 8.2 66.5 ± 7.0 68.6 ± 8.3 0.50 
LVEDD, mm 46.6 ± 6.3  46.3 ± 6.7 46.7 ± 5.7 46.7 ± 6.5 0.56 
LVESD, mm 25.2 ± 6.5  25.4 ± 6.1 25.4 ± 6.7 24.8 ± 6.7 0.51 
LVMI, g/m2 109 ± 28.4  110 ± 33.0 107 ± 24.5 108 ± 27.3 0.60 
RWT 0.50 ± 0.09  0.51 ± 0.09 0.50 ± 0.08 0.50 ± 0.09 0.71 
Left atrial volume index, mL/m2 28.3 ± 8.5  29.1 ± 7.9 27.5 ± 8.1 28.3 ± 9.3 0.44 
E-wave velocity, cm/s 72.7 ± 17.7  73.1 ± 16.4 73.5 ± 17.0 71.5 ± 19.5 0.45 
Medial e’ wave velocity, cm/s 7.1 ± 1.5  6.9 ± 1.4 7.2 ± 1.7 7.2 ± 1.5 0.11 
E/e’ ratio 12.7 ± 3.6  13.1 ± 3.6 12.6 ± 3.7 12.3 ± 3.6 0.049 
E:A ratio 0.90 ± 0.32  0.90 ± 0.33 0.87 ± 0.26 0.93 ± 0.36 0.59 
IVRT, ms 87.1 ± 25.1  90.0 ± 26.4 86.1 ± 24.6 85.2 ± 24.3 0.13 
DT, ms 244 ± 63.2  247 ± 64.1 248 ± 68.3 236 ± 56.3 0.15 
Biomarkers, median (IQR)       
NT-proBNP, ng/L 166 (84.3-312)  187 (111-331) 142 (65.9-276) 165 (86.0-332) 0.43 
PICP, ng/mL 111 (92.0-136)  111 (88.5-135) 111 (93.2-136) 113 (92.3-138) 0.84 
Cardiopulmonary exercise testing        
Maximum exercise duration, s 539 ± 176  522 ± 167 530 ± 175 566 ± 184 0.043 
Peak VO2, mL/min/kg 16.3 ± 3.5  16.3 ± 3.5 16.0 ± 3.4 16.5 ± 3.5 0.56 
ATVO2, mL/min/kg 11.5 ± 3.2  11.5 ± 3.2 11.5 ± 3.2 11.5 ± 3.4 0.87 
VE/VCO2 slope  30.0 ± 4.2  30.8 ± 4.5 29.6 ± 4.1 29.7 ± 4.0 0.027 
Borg scale 5.2 ± 1.8  4.9 ± 1.8 5.2 ± 1.8 5.5 ± 1.8 0.005 
Six-minute walk test       
Walk distance, m 535 ± 78.2  532 ± 78.8 536 ± 69.9 539 ± 85.8 0.46 
Health-related quality of life scores       
SF-36 physical function score 62.7 ± 22.2  62.2 ± 21.1 61.3 ± 23.5 64.7 ± 22.0 0.39 
PHQ-Sum 5.7 ± 4.2  5.7 ± 4.2 5.5 ± 4.3 5.8 ± 4.1 0.98 
CITP means carboxy-terminal telopeptide of collagen type I; MMP-1, matrix metalloproteinase-1; LVEF, left 
ventricular (LV) ejection fraction; LVEDD, LV end-diastolic diameter; LVESD, LV end-systolic diameter; LVMI, 
LV mass index; RWT, relative wall thickness; E, peak early transmitral ventricular filling velocity; e’, early diastolic 
tissue Doppler velocity; A, peak atrial transmitral ventricular filling velocity; IVRT, isovolumetric relaxation time; 
DT, deceleration time; NT-proBNP, amino-terminal pro-brain natriuretic peptide; PICP, carboxy-terminal propeptide 
of procollagen type I; VO2, oxygen consumption; ATVO2, oxygen consumption at anaerobic threshold; VE, expired 
volume per unit time; VCO2, volume of expired carbon dioxide; SF-36, short form 36; PHQ-Sum, Patient Health 
Questionnaire sum score. Higher values indicate better performance for LVEF, medial e’ wave velocity, duration of 
exercise, peak VO2, ATVO2, Borg scale, walk distance and SF-36 physical function score. Lower values indicate 
better performance for left atrial volume index, E/e’ (medial) velocity ratio, VE/VCO2 slope and PHQ-Sum. Values 
are expressed as mean ± SD, median and interquartile range (IQR) and categorical variables as numbers and 
percentages. 
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Table 3. Spironolactone versus placebo differences after 12 months of treatment in patients categorized according to 
tertiles of the CITP:MMP-1 ratio  
 1st tertile (n=121)  2nd tertile (n=125)  3er tertile (124) 
 Spironolactone(n=65)-Placebo(n=56)a  Spironolactone (n=60)-Placebo (65)
a  Spironolactone(n=65)-Placebo(n=59)a 
 Difference (95% CI) P value  Difference (95% CI) P value  Difference (95% CI) P value 
CITP:MMP-1 ratio <2.50  2.50-5.49  >5.49 
Primary endpoints         
E/e’ (medial) velocity ratio -0.63 (-1.67 to 0.41) 0.23  -1.63 (-2.60 to -0.66) 0.001  -2.46 (-3.48 to -1.44) <0.0001 
Peak VO2, mL/min/kg 0.19 (-1.05 to 1.43) 0.76  -0.03 (-1.17 to 1.24) 0.96  -0.26 (-1.56 to 1.04) 0.69 
Six-minute walk test         
Walk distance, m -29.2 (-48.2 to -10.3) 0.003  -16.0 (-45.1 to 13.0) 0.28  -8.27 (-25.2 to 8.63) 0.34 
Other clinical variables         
NYHA class, n (%)         
    I         
    II 0.81 (0.25 to 2.64)b 0.73  1.70 (0.61 to 4.73)b 0.31  1.00 (0.30 to 3.37)b 0.99 
    III         
Peripheral edema, n (%) 0.70 (0.29 to 1.69)b 0.43  0.55 (0.23 to 1.32)b 0.18  0.92 (0.34 to 2.44)b 0.92 
SBP, mm Hg -5.97 (-11.6 to -0.30) 0.039  -9.86 (-15.3 to -4.42) 0.0004  -8.43 (-13.0 to -3.83) 0.0004 
DBP, mm Hg -2.79 (-6.05 to 0.48) 0.09  -3.21 (-6.19 to -0.24) 0.035  -4.28 (-7.59 to -0.97) 0.012 
HR, beats/min 0.30 (-3.24 to 3.83) 0.87  1.66 (-1.42 to 4.73) 0.29  1.63 (-1.48 to 4.74) 0.30 
Sodium, mmol/L -0.60 (-1.49 to 0.28) 0.18  -1.32 (-2.25 to -0.39) 0.006  -0.95 (-1.87 to -0.04) 0.041 
Potassium, mmol/L 0.24 (0.09 to 0.39) 0.002  0.31 (0.20 to 0.42) <0.0001  0.18 (0.05 to 0.30) 0.007 
Hemoglobin, g/dL -0.55 (-0.97 to -0.13) 0.011  -0.25 (-0.52 to 0.02) 0.07  -0.13 (-0.38 to 0.12) 0.31 
eGFR, mL/min/1.73 m2 -4.49 (-7.89 to -1.09) 0.010  -6.79 (-10.5 to -3.05) 0.0005  -3.42 (-6.89 to 0.05) 0.053 
Other echocardiographic variables         
E-wave velocity, cm/s -4.39 (-9.33 to 0.55) 0.08  -3.75 (-8.25 to 0.75) 0.10  -4.10 (-8.63 to 0.42) 0.07 
Medial e’ wave velocity, cm/s 0.33 (-0.12 to 1.77) 0.15  0.16 (-0.24 to 0.56) 0.44  0.63 (0.19 to 1.06) 0.005 
E/A velocity ratio -0.05 (-0.15 to 0.05) 0.29  -0.04 (-0.12 to 0.04) 0.30  -0.03 (-0.12 to 0.06) 0.47 
IVRT, ms 7.52 (-2.13 to 17.2) 0.13  -9.11 (-17.5 to -0.76) 0.033  -5.59 (-14.2 to 3.02) 0.20 
DT, ms 13.2 (-9.61 to 36.0) 0.25  8.08 (-12.7 to 28.9) 0.44  -7.41 (-28.9 to 14.1) 0.50 
LVEF, % 0.76 (-1.94 to 3.45) 0.58  2.48 (-0.27 to 5.24) 0.08  2.10 (-0.77 to 4.98) 0.15 
LVMI, g/m2 -6.93 (-15.1 to 1.21) 0.10  -8.47 (-16.1 to -0.84) 0.030  -3.23 (-12.1 to 5.61) 0.47 
Left atrial volume index, mL/m2 -1.09 (-3.01 to 0.83) 0.26  -0.65 (-2.49 to 1.19) 0.49  0.67 (-1.60 to 2.94) 0.56 
LVEDD, mm -1.49 (-3.64 to 0.67) 0.17  -2.23 (-4.11 to -0.35) 0.021  -0.88 (-2.88 to 1.12) 0.39 
LVESD, mm -0.26 (-2.18 to 1.66) 0.79  -0.66 (-2.70 to -1.39) 0.53  -1.24 (-3.37 to 0.89) 0.25 
Biomarkers, median (IQR)         
NT-proBNP, ng/L 0.81 (0.64 to 1.03)c 0.08  0.89 (0.68 to 1.16)c 0.39  0.84 (0.69 to 1.01)c 0.06 
26 
 
PICP, ng/mL 1.05 (0.96 to 1.14)c 0.28  0.88 (0.81 to 0.95)c 0.002  0.94 (0.87 to 1.02)c 0.15 
CITP:MMP-1 ratio 0.94 (0.72 to 1.22)c 0.63  0.97 (0.79 to 1.20)c 0.81  0.94 (0.76 to 1.16)c 0.77 
Cardiopulmonary exercise testing          
Maximum exercise duration, s -6.28 (-44.7 to 32.1) 0.75  28.31 (-11.3 to 67.9) 0.16  -4.47 (-40.9 to 31.9) 0.81 
ATVO2, mL/min/kg 0.11 (-1.18 to 1.40) 0.87  -0.74 (-1.75 to 0.27) 0.15  -0.69 (-1.94 to 0.56) 0.28 
VE/VCO2 slope  0.97 (-0.38 to 2.32) 0.16  0.89 (-0.41 to 2.20) 0.18  0.71 (-0.34 to 1.76) 0.18 
Borg scale -0.06 (-0.72 to 0.61) 0.86  0.13 (-0.40 to 0.67) 0.62  0.12 (-0.72 to 0.96) 0.78 
Health-related quality of life 
scores 
        
SF-36 physical function score 2.45 (-3.29 to 8.20) 0.40  -5.39 (-11.6 to 0.80) 0.09  6.55 (0.78 to 12.3) 0.026 
PHQ-Sum -0.48 (-1.53 to 0.57) 0.63  0.87 (-0.47 to 2.20) 0.20  -0.82 (-1.79 to 0.15) 0.10 
CITP means carboxy-terminal telopeptide of collagen type I; MMP-1, matrix metalloproteinase-1; E, peak early transmitral ventricular filling velocity; 
e’, early diastolic tissue Doppler velocity; VO2, oxygen consumption; NYHA, New York Heart Association; SBP, systolic blood pressure; DBP, diastolic 
blood pressure; HR, heart rate; eGFR, estimated glomerular filtration rate; A, peak atrial transmitral ventricular filling velocity; IVRT, isovolumetric 
relaxation time; DT, deceleration time; LVEF means left ventricular (LV) ejection fraction; LVMI, LV mass index; LVEDD, LV end-diastolic diameter; 
LVESD, LV end-systolic diameter; NT-proBNP, amino-terminal pro-brain natriuretic peptide; PICP, carboxy-terminal propeptide of procollagen type I; 
ATVO2, oxygen consumption at anaerobic threshold; VE, expired volume per unit time; VCO2, volume of expired carbon dioxide; SF-36, short form 36; 
PHQ-Sum, Patient Health Questionnaire sum score; IQR, interquartile range.  
aBetween-group differences are from analysis of covariance, adjusting for baseline. bOdds ratio (95% CI). cGeometric mean ratio (95% CI). 
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